Current status of chemotherapy of breast cancer.
作者信息
Coates A
出版信息
Drugs. 1984 Aug;28(2):93-8. doi: 10.2165/00003495-198428020-00001.
Abstract
摘要
相似文献
1
Current status of chemotherapy of breast cancer.乳腺癌化疗的现状
Drugs. 1984 Aug;28(2):93-8. doi: 10.2165/00003495-198428020-00001.
2
[Adjuvant chemo and hormone therapy in breast cancer].
Chirurg. 1984 Apr;55(4):207-10.
3
Chemotherapy and endocrine therapy in metastatic disease.
Curr Opin Oncol. 1989 Dec;1(2):324-32.
4
[Palliative therapeutic control of tumor progression in patients with metastatic breast cancer].
Internist (Berl). 1993 Apr;34(4):340-50.
5
[Medical treatment of breast carcinoma].
Ann Ital Chir. 1991 Sep-Oct;62(5):467-77.
6
7
[Adjuvant treatment of breast cancer: past, present and future].[乳腺癌的辅助治疗：过去、现在与未来]
Rev Med Brux. 1988 Jun;9(5):268-73.
8
[Questions on hormone and chemotherapy in metastatic breast cancer].[关于转移性乳腺癌中激素与化疗的问题]
Gynakol Rundsch. 1988;28 Suppl 1:76-83.
9
[Antineoplastic chemotherapies (including hormone therapy). Classification and mechanism of action].
Rev Prat. 1991 Dec 15;41(26):2759-65.
10
[Current status of adjuvant chemo- and hormone therapy in resectable breast carcinoma].
Schweiz Rundsch Med Prax. 1987 Oct 20;76(43):1193-9.
引用本文的文献
1
Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.伊达比星。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。
Drugs. 1991 Oct;42(4):690-719. doi: 10.2165/00003495-199142040-00010.
2
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.米托蒽醌。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。
Drugs. 1991 Mar;41(3):400-49. doi: 10.2165/00003495-199141030-00007.
本文引用的文献
1
Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA.晚期乳腺癌对抗代谢药物甲氨蝶呤与烷化剂噻替派联合用药的反应
J Mt Sinai Hosp N Y. 1963 May-Jun;30:246-67.
2
Reporting results of cancer treatment.癌症治疗结果报告。
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
3
Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.测量癌症患者的生活质量：一种供医生使用的简明生活质量指数。
J Chronic Dis. 1981;34(12):585-97. doi: 10.1016/0021-9681(81)90058-8.
4
Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project.
Cancer Res. 1981 Nov;41(11 Pt 1):4399-403.
5
Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
Cancer. 1982 Oct 1;50(7):1235-44. doi: 10.1002/1097-0142(19821001)50:7<1235::aid-cncr2820500703>3.0.co;2-l.
6
Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.联合化疗（CMFVP）与左旋苯丙氨酸氮芥（L-PAM）治疗腋窝淋巴结阳性的可手术乳腺癌：西南肿瘤学组研究
Cancer. 1982 Aug 1;50(3):423-34. doi: 10.1002/1097-0142(19820801)50:3<423::aid-cncr2820500307>3.0.co;2-o.
7
Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study.
Cancer. 1982 Mar 1;49(5):835-9. doi: 10.1002/1097-0142(19820301)49:5<835::aid-cncr2820490502>3.0.co;2-z.
8
Disease-free survival at intervals during and following completion of adjuvant chemotherapy: the NSABP experience from three breast cancer protocols.
Cancer. 1981 Sep 15;48(6):1273-80. doi: 10.1002/1097-0142(19810915)48:6<1273::aid-cncr2820480602>3.0.co;2-3.
9
Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial.
Cancer Treat Rep. 1980 Aug-Sep;64(8-9):981-4.
10
Can patients with breast cancer be cured of their disease? A sample of the M. D. anderson Hospital experience.
Cancer. 1983 Mar 1;51(5):938-45. doi: 10.1002/1097-0142(19830301)51:5<938::aid-cncr2820510529>3.0.co;2-8.
Zotero 插件